ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Ranger Investment Management L.P.

Ranger Investment Management L.P. trimmed its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 49.2% during the third quarter, Holdings Channel reports. The firm owned 271,345 shares of the specialty pharmaceutical company’s stock after selling 262,888 shares during the quarter. ANI Pharmaceuticals comprises approximately 1.7% of Ranger Investment Management L.P.’s holdings, making the stock its 26th biggest position. Ranger Investment Management L.P.’s holdings in ANI Pharmaceuticals were worth $24,855,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the stock. Global Alpha Capital Management Ltd. grew its holdings in ANI Pharmaceuticals by 17.2% during the 2nd quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock valued at $56,251,000 after buying an additional 126,500 shares during the last quarter. Rubric Capital Management LP grew its holdings in shares of ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after buying an additional 200,998 shares in the last quarter. Mizuho Markets Americas LLC raised its position in shares of ANI Pharmaceuticals by 7.8% in the second quarter. Mizuho Markets Americas LLC now owns 212,830 shares of the specialty pharmaceutical company’s stock valued at $13,887,000 after buying an additional 15,357 shares during the last quarter. Loomis Sayles & Co. L P boosted its position in ANI Pharmaceuticals by 6.4% during the second quarter. Loomis Sayles & Co. L P now owns 206,382 shares of the specialty pharmaceutical company’s stock worth $13,466,000 after acquiring an additional 12,494 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in ANI Pharmaceuticals by 32.0% in the 2nd quarter. Bank of America Corp DE now owns 185,465 shares of the specialty pharmaceutical company’s stock worth $12,102,000 after acquiring an additional 44,916 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $84.33, for a total value of $42,165.00. Following the completion of the sale, the vice president owned 74,374 shares of the company’s stock, valued at $6,271,959.42. This trade represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Krista Davis sold 1,622 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $82.40, for a total transaction of $133,652.80. Following the sale, the senior vice president owned 58,564 shares in the company, valued at $4,825,673.60. This represents a 2.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 28,101 shares of company stock worth $2,453,063 over the last 90 days. 11.10% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $81.46 on Friday. The company has a market cap of $1.83 billion, a price-to-earnings ratio of 49.98 and a beta of 0.50. ANI Pharmaceuticals, Inc. has a 12 month low of $54.10 and a 12 month high of $99.50. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. The stock’s 50-day moving average is $81.70 and its 200-day moving average is $85.34.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.74 by $0.30. The business had revenue of $227.81 million during the quarter, compared to analysts’ expectations of $211.92 million. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The company’s revenue for the quarter was up 53.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.34 EPS. Equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ANIP shares. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Guggenheim increased their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Truist Financial raised their price target on ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. Barclays started coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective for the company. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $103.43.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.